JUN 2013

EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.

Issue link: https://digital.eyeworld.org/i/137624

Contents of this Issue


Page 73 of 74

Introducing an advanced formulation of BROMDAY® (bromfenac ophthalmic solution) 0.09% PROLENSA™ POWERED FOR PENETRATION PROLENSA™ delivers potency and penetration with QD efficacy1,2 Advanced formulation delivers corneal penetration1-3 Proven efficacy at a lower concentration1 Available in 1.6-mL and 3-mL bottle sizes IMPORTANT RISK INFORMATION ABOUT PROLENSA™ Indications and Usage PROLENSA™ (bromfenac ophthalmic solution) 0.07% is a nonsteroidal antiinflammatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Dosage and Administration Instill one drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post surgery. Please see brief summary of full Prescribing Information on adjacent page. References: 1. PROLENSA™ Prescribing Information, April 2013. 2.'DWDRQĆOH%DXVFK/RPE,QFRUSRUDWHG3.%DNOD\DQ*$ 3DWWHUVRQ+06RQJ&.*RZ-$0F1DPDUD75KRXUHYDOXDWLRQRIWKHRFXODUGLVWULEXWLRQRI14&ODEHOHGEURPIHQDFIROORZLQJWRSLFDO instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008;24(4):392-398. píDUHWUDGHPDUNVRI%DXVFK/RPE,QFRUSRUDWHGRULWVDIĆOLDWHV k%DXVFK/RPE,QFRUSRUDWHG3ULQWHGLQ86$8635$E Warnings and Precautions æ6XOĆ WHDOOHUJLFUHDFWLRQV æ,QFUHDVHGEOHHGLQJRIRFXODUWLVVXHV æ6ORZRUGHOD\HGKHDOLQJ æ&RUQHDOHIIHFWVLQFOXGLQJNHUDWLWLV æ3RWHQWLDOIRUFURVVVHQVLWLYLW\ æ&RQWDFWOHQVZHDU Adverse Reactions The most commonly reported adverse reactions in 3%-8% of patients were anterior chamber inflammation, foreign body sensation, eye pain, photophobia, and blurred vision.

Articles in this issue

Archives of this issue

view archives of Eyeworld - JUN 2013